These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21504185)

  • 1. Palladium complexes affect the aggregation of human prion protein PrP106-126.
    Wang Y; Feng L; Zhang B; Wang X; Huang C; Li Y; Du W
    Inorg Chem; 2011 May; 50(10):4340-8. PubMed ID: 21504185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gold complexes inhibit the aggregation of prion neuropeptides.
    Wang X; He L; Zhao C; Du W; Lin J
    J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes.
    Wang X; Zhang B; Zhao C; Wang Y; He L; Cui M; Zhu X; Du W
    J Inorg Biochem; 2013 Nov; 128():1-10. PubMed ID: 23911565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
    Wang X; Zhu D; Zhao C; He L; Du W
    Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes.
    Wang X; Cui M; Zhao C; He L; Zhu D; Wang B; Du W
    Inorg Chem; 2014 May; 53(10):5044-54. PubMed ID: 24787240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126.
    Kanapathipillai M; Ku SH; Girigoswami K; Park CB
    Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of gold-bipyridyl derivants on aggregation and disaggregation of the prion neuropeptide PrP106-126.
    Zhao C; Wang X; He L; Zhu D; Wang B; Du W
    Metallomics; 2014 Nov; 6(11):2117-25. PubMed ID: 25273168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide NMHRYPNQ of the cellular prion protein (PrP(C)) inhibits aggregation and is a potential key for understanding prion-prion interactions.
    Rehders D; Claasen B; Redecke L; Buschke A; Reibe C; Jehmlich N; von Bergen M; Betzel C; Meyer B
    J Mol Biol; 2009 Sep; 392(1):198-207. PubMed ID: 19607841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
    Kourie JI
    Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.
    Tagliavini F; Forloni G; Colombo L; Rossi G; Girola L; Canciani B; Angeretti N; Giampaolo L; Peressini E; Awan T; De Gioia L; Ragg E; Bugiani O; Salmona M
    J Mol Biol; 2000 Jul; 300(5):1309-22. PubMed ID: 10903871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
    Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
    J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PrP106-126 peptide disrupts lipid membranes: influence of C-terminal amidation.
    Zheng W; Wang L; Hong Y; Sha Y
    Biochem Biophys Res Commun; 2009 Feb; 379(2):298-303. PubMed ID: 19103159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of the pathogenic conformational change of the prion protein by an attractor of low order.
    Havsteen BH
    J Theor Biol; 2004 Nov; 231(1):39-48. PubMed ID: 15363928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p75(NTR) activation of NF-kappaB is involved in PrP106-126-induced apoptosis in mouse neuroblastoma cells.
    Bai Y; Li Q; Yang J; Zhou X; Yin X; Zhao D
    Neurosci Res; 2008 Sep; 62(1):9-14. PubMed ID: 18602709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of the 106-126 prion peptide with lipid membranes and potential implication for neurotoxicity.
    Dupiereux I; Zorzi W; Lins L; Brasseur R; Colson P; Heinen E; Elmoualij B
    Biochem Biophys Res Commun; 2005 Jun; 331(4):894-901. PubMed ID: 15882962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc, copper, and carnosine attenuate neurotoxicity of prion fragment PrP106-126.
    Kawahara M; Koyama H; Nagata T; Sadakane Y
    Metallomics; 2011 Jul; 3(7):726-34. PubMed ID: 21442127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.